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 INTRODUCTION 
 Enteric fever is an infection caused by either typhoid bac-
teria ( Salmonella enterica serotype typhi) or paratyphoid bac-
teria ( S. enterica paratyphi A, B, and C). The disease remains a 
serious public health problem in southern and Southeast Asia 
where the incidence can be as high as 100 cases/100, 000 popu-
lation/year. It is estimated that enteric fever causes 22 million 
episodes of illness and more than 200,000 deaths globally each 
year. 1, 2 Enteric fever is still seen in resource-rich areas usu-
ally as an imported infection among travelers and migrants. 
Occasional infections occur in contacts of asymptomatic car-
riers of  S. enterica . Estimates of the incidence of enteric fever 
among returning travelers are 3–30 cases/100,000 travelers. 3 
 Since 2000, all patients admitted to the Hospital for Tropical 
Diseases in London have had their clinical and laboratory 
data prospectively entered into a database. Over the past 
9 years, we have seen 92 cases of microbiologically confirmed 
enteric fever. We report the demographic, clinical, and labora-
tory features of these patients and their response to treatment, 
in what we believe is the largest series of enteric fever in adult 
returning travelers in the literature to date. 
 METHODS 
 A case of enteric fever was defined as isolation of  S. enter-
ica serotypes typhi or paratyphi A, B, and C from a sterile site 
(blood, bone marrow aspirate, or urine) or isolation from stool 
in a patient with clinical features compatible with enteric fever. 
 Cases were identified from a database of all adult patients 
admitted to the Hospital for Tropical Diseases during 2000–
2009, where the diagnosis made by the attending physician is 
entered prospectively. Patients less than 16 years of age are not 
seen at the Hospital for Tropical Diseases. Epidemiological, 
demographic, clinical, radiological, and microbiological, as 
well as treatment and outcomes data were gathered retrospec-
tively from patients’ notes and laboratory records. Some data 
were missing from patients’ notes and these are noted in the 
analyses. 
 Time to defervescence was defined as a temperature 
< 37.5°C for at least 48 hours without an antipyretic. Relapse 
was defined as recurrence of symptoms with a positive culture 
from a sterile site (blood, bone marrow aspirate, or urine) or 
isolation from stool in a patient with clinical features compat-
ible with enteric fever. 
 Organisms isolated from blood cultures, stool, urine, and 
bone marrow were identified by using the API 20E system 
(bioMérieux, Marcy l’Etoile, France). Before full identifica-
tion, antibiotic susceptibility patterns for coliforms in gen-
eral would have been determined and these include testing 
for ampicillin, ciprofloxacin, trimethoprim, nalidixic acid, 
and ceftriaxone resistance by using the British Society of 
Antimicrobial Chemotherapy standard disc susceptibility 
method. In addition, specific susceptibility to chlorampheni-
col was determined for all  Salmonella spp. Since 2002, nali-
dixic acid resistance was used to identify those isolates with 
reduced susceptibility to ciprofloxacin. Because this proce-
dure does not detect all cases, ciprofloxacin minimum inhibi-
tory concentrations (MICs) were determined by using E test 
strips since 2003. 
 Isolates were defined as either fully susceptible (to the 
first-line antimicrobial drugs ampicillin, chloramphenicol, 
and trimethoprim-sulfamethoxazole [co-trimoxazole]), multi-
drug-resistant (exhibiting resistance to first-line antimicrobial 
drugs), demonstrating decreased ciprofloxacin susceptibility 
or nalidixic acid resistance (DCS/Na R ) 4 (ciprofloxacin MIC = 
0.125–1.0 mg/L), or fluoroquinolone resistant (ciprofloxacin 
MIC > 1 mg/L). 
 For continuous variables, means and standard deviations 
are shown. For normally distributed data and non-normal 
data, geometric means and ranges are shown. Student’s  t -test 
was used to analyze quantitative variables and Fisher’s exact 
test was used to test for categorical variables. 
 RESULTS 
 Between August 2000 and January 2009, 92 cases of enteric 
fever were diagnosed. Over this same period, 4,061 cases of 
enteric fever were reported to the Health Protection Agency 
Center for England and Wales. 5 
 Demographics and travel history.  The mean ± SD age of 
patients was 35 ± 12 years. Most (84 of 88, 96%) of them were 
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usually resident in a developed country, and four (5%) were 
either visiting or recent immigrants to the United Kingdom. 
Most patients were either Asian (49%) or white (41%), and 
most (70%) acquired their infection in southern Asia. One 
person had not traveled outside the United Kingdom but was 
Pakistani, and another person, originally from Somalia, had 
last traveled six months earlier and may have become infected 
in the United Kingdom ( Table 1 ). 
 Most patients were either visiting friends and relatives 
(40 of 87, 46%) or were on holiday (25 of 87, 29%). The average 
duration of travel was approximately eight weeks (median = 
33 days, range = 7–404 days). Vaccination status was known for 
40 patients; 22 (55%) had received typhoid vaccination within 
the previous three years, although most of these patients 
(17 of 22) were infected with  S. paratyphi . Of the 18 patients 
who reported not having received vaccination, 12 (67%) were 
infected with  S. typhi . 
 Clinical features.  Symptoms usually began in the week before 
(14%), or within the first three weeks after (74%) arrival in the 
United Kingdom ( Table 2 ). All patients had a history of fever 
and 67 (82%) of 82 were febrile at presentation; 50 (60%) 
of 83 reported a fever and gastrointestinal symptoms; and 
26 (31%) reported a cough. Relative bradycardia (as defined 
by Cunha 6 ) was uncommon, occurring in only 11 (13%) of 
82 patients. Splenomegaly was present in 11 (13%) of 84 
patients, and rose spots were rarely seen (3 of 83, 4%). Two 
patients, both infected with  S. paratyphi A, had complicated 
infections; one had a rectal bleed and the other had an 
appendiceal perforation diagnosed by ultrasonography. Both 
recovered after receiving conservative treatment. 
 Laboratory investigations.  Virtually all patients (83 of 
91, 91%) had normal total leukocyte counts, although a 
significant proportion were lymphopenic (36 of 90, 40%) 
( Table 3 ). All patients had an elevated C-reactive protein level 
on admission; in 33 (36%) it was > 100 mg/L. The erythrocyte 
sedimentation rate was normal for 20 patients (29%). Most 
had a significant transaminitis, with almost all (75 of 91, 82%) 
having an increased level of alanine aminotransferase (ALT) 
during their illness. The maximum ALT level was three times 
the upper reference limit at some time during admission in 
56 (62%) of patients. None of the 31 (34%) patients tested 
for co-infection with hepatotrophic viruses (hepatitis A, B, 
C, and E viruses, cytomegalovirus, Epstein-Barr virus, or 
parvovirus) had positive serologic results. Laboratory indices 
were compared between persons with typhoid infections and 
those with paratyphoid infections. There were no significant 
differences between them except for two characteristics: 
paratyphoid was associated with a lower neutrophil count 
and typhoid was associated with a lower hemoglobin level 
in males. 
 Microbiologic results.  Blood cultures showed the highest 
levels of positive results (91%, n = 91), usually within 48 hours 
(mean ± SD = 37.0 ± 14.9 hours). Stool cultures showed a 
lower yield of 40% (n = 78) and tended to become positive 
later than blood (mean ± SD = 105.0 ± 42.3 hours). 
 Seven patients had only positive stool cultures. Two of 
75 urine samples were also positive, one from a patient with 
negative results for blood and stool cultures. Only one patient 
provided a bone marrow sample, which had a positive culture. 
Samples were taken 1–48 days after onset of symptoms (mean ± 
SD = 11 ± 8 days, n = 84 days). No significant differences were 
 T able 2 
 Clinical characteristics of patients with enteric fever, London, United 
Kingdom * 
Characteristic No. (%)
Onset of symptoms in relation to 
arrival in United Kingdom (n = 84)
2–5 weeks prior 3 (4)
1 week prior 12 (14)
1–7 days 18 (21)
8–14 days 28 (33)
15–21 days 16 (19)
> 22 days 7 (8)
Symptom (n = 83)
Fever 33 (40)
GI symptoms 0
Fever and GI symptoms 50 (60)
Cough 26 (31)
Examination findings
Fever (temperature > 37°C) (n = 82) 67 (82)
Tachycardia (n = 82) 41 (50)
Relative bradycardia (n = 82) 11 (13)
Splenomegaly (n = 84) 11 (13)
Rose spots (n = 83) 3 (4)
 * n = total number of patients for which data were available; GI = gastrointestinal. 
 T able 1 
 Demographics and travel characteristics of patients with enteric fever, 
London, United Kingdom * 
Characteristic Value
Male sex (n = 92) 56 (61)
Country of residence (n = 88)
United Kingdom 83 (94)
Nigeria 2 (2)
United States 1 (1)
India 1 (1)
South Africa 1 (1)
Country of birth (n = 87)
Developed 45 (52)
Developing 42 (48)
Ethnic origin (n = 90)
Asian 44 (49)
White 37 (41)
Black 6 (7)
Chinese 1 (1)
Other 2 (2)
Number of countries visited (n = 87)
0 1 (1)
1 64 (74)
2 15 (17)
3 3 (3)
4 2 (2)
5 2 (2)
Destination/source of isolate (n = 87)
Southern Asia 61 (70)
Southeast Asia 6 (7)
Western Asia (Turkey) 1 (1)
Western Africa 8 (9)
Eastern Africa 2 (2)
South America (Bolivia) 1 (1)
Multiple regions 7 (8)
No travel 1 (1)
Reason for travel (n = 87)
Visiting friends or relatives 40 (46)
Tourism 25 (29)
Business 17 (20)
Visiting or immigrated to the United Kingdom 4 (5)
No travel 1 (1)
Median duration of travel, days (range) (n = 80) 33 (7–404)
 * Values are no. (%) unless otherwise indicated. n = total number of patients for which 
data were available. 
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found in culture positivity of blood or stool from patients with 
typhoid infections or those with paratyphoid infections. 
 Almost equal proportions of infections were  S. typhi 
(47 cases) or  S. paratyphi (45 cases). Infections acquired in 
southern Asia were equally likely to be  S. typhi or  S. paratyphi A. 
In comparison, patients who traveled to Southeast Asia 
were more likely to have acquired  S. paratyphi A infection 
(6 of 7 cases). The one case of infection with  S. paratyphi B had 
traveled in Bolivia. 
 Antibiotic susceptibility patterns are shown in  Table 4 . 
Fourteen of the  S. typhi isolates (30%) were fully susceptible 
to first-line antimicrobial drugs. Twenty-six (57%), all from 
southern Asia, were DCS/Na R and 14 isolates (30%) were 
multidrug resistant. All of these isolates were from southern 
Asia and Nigeria. 
 None of the paratyphoid isolates were multidrug resis-
tant. However, DCS/Na R rates were higher than in persons 
infected with  S. typhi (74%). One patient who had been trav-
eling throughout southern and Southeast Asia acquired an 
infection with an isolate that showed full fluoroquinolone 
resistance (MIC = 8.0 mg/L), but the isolate was susceptible 
to first-line antimicrobial drugs. Ten (11%) patients also had 
other gastrointestinal infections diagnosed during their admis-
sion ( Campylobacter spp., giardiasis, shigellosis, and ascaria-
sis), which implied exposure to poor food/water hygiene. 
 Treatment and outcomes.  Treatment data were available 
for 4 (91%) of 92 patients. Once the diagnosis was suspected, 
all patients were treated with azithromycin, ciprofloxacin, 
or ceftriaxone until culture results were available. Because 
patients often received more than one antimicrobial drug, 
antibiotic-specific times to defervescence were rarely calcu-
lated. Overall, however, fever abated in 6.2 days (n = 78). 
Mean time to defervescence in patients infected with DCS/
Na R strains and treated with ciprofloxacin was 7.6 days (n = 5), 
which was longer than that for patients who were infected 
with fully susceptible strains (4.8 days, n = 15). 
 There was one relapse in a patient infected with a DCS/Na R 
strain of  S. paratyphi A who had initially been treated with a 
14-day course of ciprofloxacin and responded to an additional 
60-day course of ciprofloxacin. One patient infected with flu-
oroquinolone-resistant paratyphoid was treated successfully 
with a 14-day course of amoxicillin. 
 Clinical characteristics and laboratory findings were com-
pared among patients with  S. typhi infections and those with 
 S. paratyphi infections. Results showed that there were no sig-
nificant differences between the two infections ( Table 5 ). 
 DISCUSSION 
 The incidence of enteric fever decreased throughout the 
first half of the 20th century in most areas of Europe and 
 T able 3 
 Hematologic and biochemical characteristics of patients with enteric fever * 
Parameter All patients Infected with  Salmonella typhi Infected with  S. paratyphi 
Total leukocytes, × 10 3 /μL (n = 91) 6.2 ± 2.0 (2.4–11.4) 6.6 ± 1.9 (3.2–10.8) 5.8 ± 2.1 (2.4–11.4)
Neutrophils, × 10 3 /μL (n = 90) 4.1 ± 1.5 (1.2–8.8) 4.5 ± 1.5 † (2.0–8.8) 3.8 ± 1.5 (1.2–7.7)
Lymphocytes, × 10 3 /μL (n = 90) 1.5 ± 0.8 (0.4–5.2) 1.6 ± 0.7 (0.7–4.5) 1.5 ± 0.9 (0.4–5.2)
Hemoglobin, g/dL
Males (n = 56) 14.1 ± 1.3 (11.3–17.6) 13.8 ± 1.2 † (11.3–16.9) 14.5 ± 1.4 (11.7–17.6)
Females (n = 35) 12.6 ± 1.4 (8.9–14.8) 12.2 ± 1.6 (8.9–14.5) 13.0 ± 1.0 (11.2–14.8)
Bilirubin, mg/dL (n = 91) 11.5 ± 7.1 (2.0–63.0) 12.1 ± 9.0 (2.0–63.0) 10.9 ± 4.5 (4.0–27.0)
Maximum (n = 90) 13.2 ± 7.9 (4.0–63.0) 14.3 ± 9.7 (4.0–63.0) 12.2 ± 5.6 (5.0–31.0)
ALT, IU/L (n = 91) 108.9 ± 131.1 (9.0–768.0) 111.6 ± 126.0 (15.0–744.0) 106.2 ± 137.4 (9.0–768.0)
Maximum (n = 90) 224.3 ± 203.1 (11.0–898.0) 239.0 ± 196.8 (18.0–752.0) 209.0 ± 210.7 (11.0–898.0)
Serum albumin, g/L (n = 91) 41.1 ± 3.6 (29.0–48.0) 40.7 ± 3.5 (34.0–47.0) 41.4 ± 3.8 (29.0–48.0)
Sodium, mmol/L (n = 82) 134.7 ± 3.6 (124.0–143.0) 133.7 ± 3.7 (124.0–140.0) 135.8 ± 3.2 (129.0–143.0)
CRP, mg/L (n = 91) 96.2 ± 21.0 (9.0–318.0) 97.7 ± 56.1 (9.0–261.0) 94.6 ± 75.7 (11.0–318.0)
ESR, mm/hr (n = 68) 33.7 ± 21.0 (2.0–116.0) 35.0 ± 22.3 (10.0–116.0) 32.3 ± 19.9 (2.0–94.0)
 * Values are mean ± SD (range). ALT = alanine aminotransferase; CRP = C-reactive protein; ESR = erythrocyte sedimentation rate. Reference ranges: leukocytes = 3.0–10.0 × 10 3 /μL; neutrophils = 
2.0–7.5 × 10 3 /μL; lymphocytes = 1.5–4.0 × 10 3 /μL; hemoglobin = 11.5–15.5 g/dL; bilirubin = 0–20.0 mg/dL; ALT = 10–35 IU/L; albumin = 34–50 g/L; sodium = 135–145 mmol/L; CRP = 0–5.0 mg/L; 
ESR = 1–20 mm/hr. 
 † P < 0.05. 
 T able 5 
 Comparison of clinical characteristics of patients with infected with 
 Salmonella typhi versus those infected with  S. paratyphi , London, 
United Kingdom * 
Characteristic  S. typhi  S. paratyphi  P 
Mean length of 
in-patient stay, days 5.9 (n = 47) 6.4 (n = 45) NS
Mean temperature 
on admission, °C 38.2 (n = 42) 38.1 (n = 41) NS
Mean heart rate on 
admission, bpm 104 (n = 41) 98 (n = 41) NS
Mean time to 
defervescence, days 5.8 (n = 41) 6.6 (n = 38) NS
Relative bradycardia, 
% of total 15 (n = 41) 12 (n = 41) NS
Splenomegaly, 
% of total 10 (n = 42) 17 (n = 42) NS
Rose spots, 
% of total 5 (n = 42) 2 (n = 41) NS
 * NS = not significant; bpm = beats per minute. 
 T able 4 
 Antimicrobial drug susceptibility patterns in  Salmonella typhi and 
 S. paratyphi , London, United Kingdom * 
Antimicrobial 
susceptibility pattern
 S. typhi , no. (%) 
(n = 46)
 S. paratyphi , no. (%) 
(n = 43)
Fully susceptible 14 (30) 10 (23)
DCS or Na R 26 (57) 32 (74)
FQR † 0 1 (2)
MDR ‡ 14 (30) 0
MDR and DCS 11 (24) 0
 *  DCS = decreased ciprofloxacin susceptibility; Na R = Nalidixic acid resistant; FQR = 
fluoroquinolone resistant; MDR = multidrug resistant. 
 †  Minimum inhibitory concentration > 1.0 mg/L. 
 ‡  Resistance to ampicillin, chloramphenicol, and trimethoprim/sulfamethoxazole 
(co-trimoxazole). 
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North America as a result of improvements in sanitation and 
hygiene and effective public health programs. 7 The increase of 
enteric fever cases in temperate countries over the past few 
decades is largely the result of foreign travel. 8 The data pre-
sented in this report highlight some of the key features that 
would alert the clinician to the possibility of enteric fever as 
the cause of a significant ongoing febrile illness in the return-
ing traveler. Many of these findings corroborate those recently 
published by Clark and others in their study of culture-
confirmed cases of enteric fever in a regional infectious dis-
eases center in Leicester, United Kingdom. 9 
 Consistent with results of other studies on returning travel-
ers and surveillance data for the United Kingdom, we found 
that southern Asia appears to be the most common source of 
infections with  S. typhi or  S .  paratyphi . 10– 15 Although enteric 
fever typically affects children and young adults in disease-
endemic countries, with most infected patients being less than 
19 years of age, 16– 18 this age distribution is not reflected in the 
population of travelers that acquire the disease. 
 The risk among those visiting friends and relatives has been 
reported to be up to 10 times higher than in those who are 
on holiday. 19, 20 Reasons for this finding include a failure to 
access pre-travel advice, either as a result of language barriers 
or poor access to health services, concerns over immunization 
costs and mistaken beliefs that previous infection or immu-
nization confer lifelong cross-protective immunity. 21 Although 
this study had no denominator data, we also found far more 
persons visiting friends and relatives had acquired the disease 
compared with tourists. In terms of length of stay, the average 
for all travelers was more than eight weeks, which is consistent 
with results of another study that suggested an increased risk 
of acquiring disease with a longer duration of stay. 22 
 Previous studies have identified  S. typhi as the dominant 
pathogen among the local population in disease-endemic 
countries, but  S. paratyphi A is increasingly being recognized 
as the cause of enteric fever, particularly in many regions of 
Asia. 1, 23– 26 However, in other countries, such as Nepal and 
Israel,  S. typhi infection still predominates. 12, 23 Equal propor-
tions of  S. typhi and  paratyphi were found among travelers in 
this study, which may reflect this change in epidemiology in 
disease-endemic countries and different modes of transmis-
sion suggested for the two pathogens. The spread of  S. typhi 
is more commonly associated with person-to-person transmis-
sion and that of  S. paratyphi with consumption of contami-
nated food. 27 Importantly, although it is traditionally taught 
that infection with  S. paratyphi causes milder disease with a 
shorter incubation than with  S. typhi , we found no differences 
between groups of patients in terms of length of illness, hema-
tologic and biochemical markers, or time to defervescence, 
which is consistent with findings in more recent reports. 12, 28, 29 
Both patients in our study who had complications had  S. para-
typhi A infections, which is consistent with recent data sug-
gesting higher rates of complications in patients infected with 
 S. paratyphi than in those infected with  S. typhi . 12, 30 
 Although it was not possible to establish when infection was 
acquired, a significant proportion of patients had symptoms 
within the first three weeks of returning, which is compat-
ible with the suggested typical incubation period of 7–14 days 
(range = 3–60 days). 31 In the absence of fever in the medical 
history, a diagnosis is highly unlikely. In addition, most patients 
did not have relative bradycardia and only a few had rose spots. 
A previous study suggested that rose spots are not found in 
patients with  S. paratyphi infection, but two of three patients 
with rose spots had enteric fever caused by  S. paratyphi . 32 
 One study suggested that anemia, leukopenia, and liver 
involvement with elevated levels of aminotransferases and 
bilirubin are common in persons with typhoid and paraty-
phoid. 33 In comparison, most patients in our study had normal 
hemoglobin levels and leukocyte counts, although lymphope-
nia was a frequent finding. That anemia and jaundice are more 
frequent findings in children and are less common in adults 
may account for the apparent discrepancy in our study. 16, 34, 35 
Elevated levels of ALT in our patients, up to 25 times the 
upper reference limit, were seen although levels in persons 
with enteric fever are rarely as high as those found in persons 
with acute viral hepatitis. 34 Whether this is a feature of the 
disease or an effect of the drug treatment is debatable, but it 
would appear that a transaminitis (levels ≤ 900 IU/L) may be 
expected in adult patients with enteric fever. 
 Isolation of  S. typhi or  paratyphi in stool alone may not be 
sufficient to confirm the diagnosis of enteric fever because it 
may simply represent a carrier state. However, in the presence 
of pyrexia or a reliable history of febrile episodes, stool cul-
tures may be diagnostic when blood cultures fail, as shown for 
seven patients in our study. 
 The optimal antimicrobial drug for treatment of persons 
with enteric fever should have a high cure rate, a short time 
to defervescence, and low relapse and fecal carriage rates. 
Therefore, selection of the most appropriate agent must 
involve consideration of the probabilities for partial and com-
plete drug resistance. In this series,  S. paratyphi isolates were 
more likely to show reduced susceptibilities to fluoroquino-
lones than  S. typhi , but they showed low rates of multidrug 
resistance, which is carried on a plasmid conferring resistance 
to first-line antimicrobial drugs ampicillin, chloramphenicol, 
and trimethoprim/sulfamethoxazole. This finding is consistent 
with other data for the United Kingdom. 9, 36 However, these 
differences cannot be used in making decisions on use of anti-
microbials because we have shown that clinical features do not 
enable distinction between  S. typhi and  S. paratyphi infections. 
Instead, drug choice must take into account global resistance 
patterns. 
 Thus, patients returning from countries, such as those in 
southern Asia, in which fluoroquinolone and multidrug-resis-
tant strains are prevalent, should be treated with azithromycin 
if oral therapy is indicated. However, it is currently difficult 
to confirm whether an isolate is susceptible to azithromycin 
because no breakpoints are available for disc testing of this 
drug. Ceftriaxone should be used if parenteral treatment is 
indicated. However, in persons returning from Africa, cipro-
floxacin is still the best choice. 37 This drug has a clinical cure 
rate of > 90%, a fever clearance times of 5–7 days, and relapse 
and fecal carriage rates of < 3% in patients with typhoid 
fever. 31, 33 It has been suggested that in severe disease (patients 
with persistent vomiting, severe diarrhea, abdominal disten-
sion, or complications), parenteral antimicrobial drugs (usually 
ceftriaxone) should be given for 10 days, or for at least 5 days 
after defervescence, although this recommendation is based on 
cure and relapse rates in small trials that involved children. 38, 39 
Additional data for optimal length of treatment in adult travel-
ers with severe disease and non-severe disease are needed. 
 Complications occur in 10–15% of patients, but this value 
is based largely on studies in children in endemic countries. 
However, complications are rare in travelers probably because 
1125IMPORTED ENTERIC FEVER, LONDON
of early access to medical care. 31 A similar reasoning can be 
applied to the case-fatality rate of enteric fever, which may be ≤ 
30% in some disease-endemic countries but > 1% in returning 
travelers. 40 Finally, the reported incidence of relapse is 1.5% for 
 S. typhi and 8.6% for  S. paratyphi A in disease-endemic coun-
tries. 41, 42 Patients should be warned of this possibility and to 
seek medical help if symptoms recur 2–3 weeks after resolu-
tion of the initial fever. 
 Although retrospective studies such as our study have lim-
itations such as recording bias, this limitation is unlikely to 
be of significance for some of our main findings (laboratory 
data). These limitations will not differ between retrospective 
and prospective studies. However, other relevant limitations 
include the fact that our study was not conducted in a special-
ized research unit. Our study was a case series that spanned 
many years, involved many physicians during this period, and 
occasionally used incomplete data. 
 Despite these drawbacks, our study highlights the clinical 
features that should alert a physician caring for febrile return-
ing travelers to the diagnosis of enteric fever, particularly those 
who visited friends and relatives and are seeking treatment 
within three weeks of returning. Rose spots and relative bra-
dycardia should not be considered common findings in these 
patients and  S. typhi and  S. paratyphi infections result in an 
almost indistinguishable clinical picture. A normal leukocyte 
count and serum bilirubin level, increased levels of inflam-
matory markers, and markedly increased ALT levels make an 
accurate diagnosis more likely. 
 With increasing drug resistance of  S. typhi and  S. paratyphi 
isolates, persons who returned from southern and Southeast 
Asia should be treated with azithromycin or ceftriaxone if 
intravenous therapy is indicated. Persons who returning from 
Africa should be treated with ciprofloxacin. 
 Received January 4, 2010. Accepted for publication February 25, 
2010. 
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